Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, hemostatic and metabolic effects and contraceptive efficacy of an oral monophasic contraceptive containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate (CG5025) used in two different regimens of intake

Next Previous
Search
Trial Profile

Safety, hemostatic and metabolic effects and contraceptive efficacy of an oral monophasic contraceptive containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate (CG5025) used in two different regimens of intake

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethinylestradiol/chlormadinone (Primary)
  • Indications Pregnancy
  • Focus Adverse reactions
  • Sponsors Grunenthal

    • Most Recent Events

    • 01 Aug 2022 Status changed to completed.
    • 25 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top